CVRx (CVRX)
NASDAQ:CVRX
Want to see CVRX full AI Analyst Report?
CVRX Stock Chart & Stats
$7.36
-$0.03(-0.21%)
At close: 4:00 PM EST
$7.36
-$0.03(-0.21%)
Day’s Range― - ―
52-Week Range$4.37 - $11.30
Previous CloseN/A
Volume20.10K
Average Volume (3M)197.28K
Market Cap
$162.13M
Enterprise Value$148.87M
Total Cash (Recent Filing)$72.30M
Total Debt (Recent Filing)$59.03M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 04, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding26,535,944
10 Day Avg. Volume162,574
30 Day Avg. Volume197,283
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.71
Price to Sales (P/S)3.27
P/FCF Ratio-4.54
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue2.52
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
$10.50Price Target Upside42.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.95
Revenue Forecast (FY)$65.32M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ExpansionActivation of the BENEFIT‑HF trial and secured CMS Category B coverage could expand the device's addressable market and raise awareness among cardiology specialists, supporting higher procedure volumes if the study succeeds.
Commercial ProductivityA revamped commercial strategy prioritizing high‑potential accounts combined with improving salesforce productivity is driving stronger device utilization and could help sustain revenue momentum.
Reimbursement ImprovementsImplementation of Category I reimbursement codes and a new billing code that increased Medicare Advantage prior authorization approvals should reduce reimbursement friction and improve commercial access for Barostim.
Bears Say
Rising Expenses And Cash RiskGuidance implying a substantial planned increase in operating expenses, together with investor concern about the cash position, makes achieving cash‑flow breakeven more challenging and has weighed on valuation.
Salesforce DisruptionSalesforce reorganization and elevated turnover have disrupted account relationships and reduced representative productivity, increasing execution risk for expansion into new centers.
Treatment Center ClosuresFewer active treatment centers and closures of smaller, lower‑utilization centers reduced net account additions and represent a near‑term operational weakness for adoption.
CVRx News
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $4.37 and its highest was $11.30 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $162.13M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Aug 04, 2026 which is in 71 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on May 11, 2026. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.504 by $0.004.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.52.
How many shares outstanding does CVRx have?
CVRx has 26,535,944 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.504. Following the earnings report the stock price went down -23.844%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CVRx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (42.66% Upside)
$10.50 (42.66% Upside)
Blogger Sentiment
Bullish
CVRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 207.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $170.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.42%
12-Months-Change
Fundamentals
Return on Equity
-120.77%
Trailing 12-Months
Asset Growth
-23.04%
Trailing 12-Months
Company Description
CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly constructive operational and commercial picture: strong top-line growth (+20% total, +22% U.S.), margin expansion (87% gross margin), ASP improvement and clear progress on the major clinical trial (BENEFIT-HF) and reimbursement milestones (Category I CPT code). Near-term headwinds are primarily administrative and timing-related (Medicare Advantage prior authorization volatility), plus continued operating losses and elevated operating expense guidance. The positives — revenue acceleration, improving gross margin, clinical trial activation, and reimbursement progress — outweigh the short-term challenges, which management characterizes as addressable and temporary.View all CVRX earnings summariesCVRX Stock 12 Month Forecast
Average Price Target
$10.50
▲(42.66% Upside)
Technical Analysis
Ownership Overview
28.72% Insiders
6.09% Mutual Funds
31.86% Other Institutional Investors
27.19% Public Companies and
Individual Investors